Loading chat...
TX HB3717
Bill
Status
3/4/2025
Primary Sponsor
Cody Harris
Click for details
AI Summary
-
Establishes a grant program administered by the Health and Human Services Commission to fund FDA drug development trials for ibogaine as a treatment for opioid use disorder, co-occurring substance use disorders, and other neurological or mental health conditions
-
Requires grant recipients to be corporate entities (for-profit, nonprofit, or public benefit) with capacity to conduct FDA trials, seek breakthrough therapy designation, and submit investigational new drug (IND) applications in accordance with 21 C.F.R. Part 312
-
Mandates a 1:1 matching funds requirement where selected applicants must contribute money equal to the grant amount received from the state toward ibogaine treatment development
-
Creates a selection committee composed of subject matter experts, philanthropic partners, and legislative designees to review applications and recommend candidates to conduct the trials
-
Requires applicants to provide plans for establishing corporate presence in Texas, training medical providers, securing insurance coverage (including Medicare, Medicaid, and TRICARE), and ensuring treatment access for uninsured individuals
Legislative Description
Relating to the establishment of a grant program to fund the United States Food and Drug Administration's drug development trials with ibogaine for the purpose of securing the administration's approval as a medication for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy.
State Finances
Last Action
Laid on the table subject to call
5/12/2025